Comparison of the efficacy and cost-effectiveness of an immunologically targeted low-dose rituximab protocol with the conventional rheumatoid arthritis protocol in severe pemphigus.

Namrata Singh Sanjeev Handa Rahul MahajanNaresh SachdevaDipankar De

Published in: Clinical and experimental dermatology (2022)

An immunologically guided low-dose rituximab regimen can be an equally effective but more affordable alternative to conventional rituximab regimens in pemphigus.

Keyphrases

low dose
diffuse large b cell lymphoma
rheumatoid arthritis
chronic lymphocytic leukemia
hodgkin lymphoma
high dose
randomized controlled trial
early onset
disease activity
cancer therapy
systemic lupus erythematosus